arrow
Y

Yanxia Wang

southwest forestry university - china
H指数:5
被引数:310

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up

Huang, L.; Yang, X.; Li, H.; Xie, Z.; Zhu, T.; You, W.; Wang, Z.; Tan, J.; Feng, G.; Sun, Q.; et al. 23价肺炎球菌多糖疫苗单剂量的免疫持久性:一项为期6年的随访研究。Hum. Vaccines Immunother. 2025, 21, 2517489. [Google Scholar] [CrossRef] [PubMed]

2025-06-190
OA
Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial

一种新型嵌合体中国mRNA (RQ3013) SARS-CoV-2疫苗的有效性、免疫原性和安全性: 一项随机、双盲、主动对照试验

2025-05-160
OA
The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6-35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial

6-35个月健康儿童四价流感亚单位疫苗的安全性与免疫原性:一项随机、盲法和阳性对照的III期临床试验

2025-04-260
OA
Distinct Role of TP53 Co-mutations in Different EGFR Subtypes Mediating the Response to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

TP53共突变在不同EGFR亚型中调节非小细胞肺癌对EGFR酪氨酸激酶抑制剂反应的特异作用

2025-04-230
PREAI
The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in Infants: A Double-Blind, Randomized, Phase III Trial

13价肺炎球菌多糖结合疫苗 (CRM197/TT) 在婴儿中的安全性和免疫原性: 一项双盲,随机,III期试验

2024-12-160
OAAI
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial
2022-02-01145
OAAI
Safety, immunogenicity, and lot-to-lot consistency of live attenuated varicella vaccine in 1-3 years old children: a double-blind, randomized phase III trial

水痘减毒活疫苗在1-3岁儿童中的安全性、免疫原性和批次一致性: 一项双盲、随机III期试验

2019-01-245
OAAI